For more than 25 years, the Biosensors International Group (“Biosensors”) has been developing and marketing critical care catheter systems and related devices used during heart surgery and intensive care treatment.
Continually striving to be at the forefront of product innovation, with a focus on improving patient outcomes today, we are driving the development of tomorrow’s next generation medical technology.
In the year 2000 we entered the interventional cardiology market and immediately became the first cardiology company to develop and patent their own proprietary limus agent, Biolimus A9™ (BA9™), a highly lipophilic1 anti-restenotic drug designed for cardiovascular stent technologies.
We were also the first stent company to develop and launch a biodegradable polymer stent with only the abluminal side coated with polymer and drug to reduce systemic exposure.
Over the last two-decades Biosensors has become one of the largest manufacturers and suppliers of cardiovascular stents globally.
Through our high quality medical devices, we impact the lives we touch, and we are committed to continue investing in and developing pioneering medical technology, pharmacological research, and engineering new medical devices that will further benefit our patients.
This will create the greatest possible patient outcomes, and provide value to our stakeholders including physicians, shareholders and employees.